The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of type of salvage therapy (ST) and response to bridging therapy (BT) on CAR-T therapy outcomes for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
 
Arushi Khurana
No Relationships to Disclose
 
Abdullah S. Al Saleh
No Relationships to Disclose
 
Sangeetha Gandhi
No Relationships to Disclose
 
Tuan Truong
No Relationships to Disclose
 
Eva Brandes
No Relationships to Disclose
 
Breanna Estby
No Relationships to Disclose
 
Gina Lange
No Relationships to Disclose
 
Jose Caetano Villasboas
Consulting or Advisory Role - Kite/Gilead (Inst)
 
Jonas Paludo
Research Funding - Celgene (Inst)
 
N. Nora Bennani
Consulting or Advisory Role - Adicet Bio (Inst); Purdue Pharma (Inst); Seagen (Inst); Verastem (Inst)
Research Funding - Kite/Gilead (Inst)
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - Affimed Therapeutics (Inst); AI Therapeutics (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Regeneron (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Patrick B. Johnston
Consulting or Advisory Role - BTG
 
Yi Lin
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gamida Cell (Inst); Juno Therapeutics (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Legend Biotech (Inst); Novartis (Inst); Sorrento Therapeutics (Inst); Vineti (Inst)
Research Funding - Bluebird Bio (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Merck (Inst); Takeda (Inst)